Please assess the completion status of the following clinical trial:

Trial Title: Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients of more than 18 years of age~* Patients presenting with anemia following chemotherapy~* Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy~  -- The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)~* Patients eligible for epoetin alfa biosimilar treatment~Exclusion Criteria:~* Patients are not receiving chemotherapy~* Patients already included in an epoetin zeta trial~* Patients presenting with a contraindication to epoetin zeta~* Patients presenting with hypersensitivity to the active principle or any of the excipients~* Patient with erythroblastopenia or acquired pure red cell aplasia (APRCA)~* Patient with uncontrollable arterial hypertension~* Patients who cannot receive adequate prophylaxis by antithrombotic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with chemo-induced symptomatic anemia (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).